Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
Previous Symbol
CUSIP04269X10
Phone303-381-6600
Debt
Debt-to-Equity Ratio0.60
Current Ratio5.62
Quick Ratio5.62
Price-To-Earnings
Trailing P/E Ratio-21.82
Forward P/E Ratio-24.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$173.77 million
Price / Sales19.53
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.04 per share
Price / Book15.32
Profitability
EPS (Most Recent Fiscal Year)($0.73)
Net Income$-147,340,000.00
Net Margins-66.77%
Return on Equity-74.02%
Return on Assets-30.79%
Miscellaneous
Employees298
Outstanding Shares213,070,000
Market Cap$3.29 billion
OptionableOptionable
Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions
What is Array Biopharma's stock symbol?
Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."
How were Array Biopharma's earnings last quarter?
Array Biopharma Inc (NASDAQ:ARRY) issued its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The biopharmaceutical company earned $56.91 million during the quarter, compared to the consensus estimate of $34.47 million. Array Biopharma had a negative return on equity of 74.02% and a negative net margin of 66.77%. The company's revenue for the quarter was up 91.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) EPS. View Array Biopharma's Earnings History.
When is Array Biopharma's next earnings date?
What price target have analysts set for ARRY?
10 analysts have issued twelve-month price targets for Array Biopharma's shares. Their predictions range from $13.00 to $33.00. On average, they anticipate Array Biopharma's share price to reach $23.3333 in the next year. This suggests a possible upside of 48.0% from the stock's current price. View Analyst Price Targets for Array Biopharma.
What is the consensus analysts' recommendation for Array Biopharma?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma.
What are Wall Street analysts saying about Array Biopharma stock?
Here are some recent quotes from research analysts about Array Biopharma stock:
- 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (10/31/2018)
- 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating with an updated $26 PT on ARRY shares. The company has an upcoming PDUFA of 6/30/18 for the combination of binimetinib/encorafenib (bini/enco), which, based on the results of the COLUMBUS study, has the potential to be best-in-class and take a market-leader position, in our view. In addition, we see further opportunity in BRAF+ CRC based on the safety lead-in portion data presented to date from the BEACON-CRC study." (6/24/2018)
Has Array Biopharma been receiving favorable news coverage?
Media coverage about ARRY stock has been trending somewhat positive on Thursday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Array Biopharma earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Array Biopharma's key competitors?
Some companies that are related to Array Biopharma include GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Bausch Health Companies (BHC), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), Amarin (AMRN), Catalent (CTLT) and GALAPAGOS NV/S (GLPG).
Who are Array Biopharma's key executives?
Array Biopharma's management team includes the folowing people:
- Mr. Ron Squarer, CEO & Director (Age 51)
- Mr. Jason Haddock, Chief Financial Officer (Age 48)
- Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)
- Mr. Curtis G. Oltmans, Exec. VP, Gen. Counsel & Sec. (Age 55)
- Dr. Victor Sandor, Chief Medical Officer (Age 52)
Who are Array Biopharma's major shareholders?
Array Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (12.72%), Vanguard Group Inc. (10.42%), BlackRock Inc. (8.04%), Franklin Resources Inc. (3.70%), American Century Companies Inc. (1.46%) and Morgan Stanley (1.37%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.
Which major investors are selling Array Biopharma stock?
ARRY stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Morgan Stanley, Teachers Advisors LLC, Franklin Resources Inc., JPMorgan Chase & Co., JPMorgan Chase & Co., Pinnacle Associates Ltd. and TIAA CREF Investment Management LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.
Which major investors are buying Array Biopharma stock?
ARRY stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Peregrine Capital Management LLC, Pictet Asset Management Ltd., Candriam Luxembourg S.C.A., American Century Companies Inc., Fosun International Ltd, Handelsbanken Fonder AB and Handelsbanken Fonder AB. View Insider Buying and Selling for Array Biopharma.
How do I buy shares of Array Biopharma?
Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Array Biopharma's stock price today?
One share of ARRY stock can currently be purchased for approximately $15.77.
How big of a company is Array Biopharma?
Array Biopharma has a market capitalization of $3.29 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.
What is Array Biopharma's official website?
How can I contact Array Biopharma?
Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]
MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
